EC Number |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
---|
1.1.1.86 | Bacterial Infections |
32198779 |
Discovery, Synthesis and Evaluation of a Ketol-Acid Reductoisomerase Inhibitor. |
causal interaction therapeutic application unassigned |
2 3 0 |
1.1.1.86 | Malaria |
17583502 |
Synthesis and evaluation of alpha,beta-unsaturated alpha-aryl-substituted fosmidomycin analogues as DXR inhibitors. |
causal interaction therapeutic application unassigned |
2 2 0 |
1.1.1.86 | Malaria |
17690389 |
Molecular epidemiology of malaria in Cameroon. XXV. In vitro activity of fosmidomycin and its derivatives against fresh clinical isolates of Plasmodium falciparum and sequence analysis of 1-deoxy-D-xylulose 5-phosphate reductoisomerase. |
diagnostic usage ongoing research unassigned |
1 3 0 |
1.1.1.86 | Malaria |
27809883 |
Alternatives to currently used antimalarial drugs: in search of a magic bullet. |
causal interaction unassigned |
1 0 |
1.1.1.86 | Malaria |
31654265 |
A computational study of the molecular basis of antibiotic resistance in a DXR mutant. |
causal interaction therapeutic application unassigned |
3 4 0 |
1.1.1.86 | Neoplasms |
33215746 |
Discovery of a Pyrimidinedione Derivative with Potent Inhibitory Activity against Mycobacterium tuberculosis Ketol-Acid Reductoisomerase. |
therapeutic application unassigned |
1 0 |
1.1.1.86 | Otitis Externa |
31322986 |
Differences in protein profiles between Malassezia pachydermatis strains obtained from healthy and infected dogs. |
diagnostic usage unassigned |
2 0 |
1.1.1.86 | Tuberculosis |
4256668 |
Biosynthesis of isoleucine & valine in Mycobacterium tuberculosis H 37 Rv. 3. Purification & properties of acetohydroxy acid isomeroreductase. |
ongoing research unassigned |
1 0 |
1.1.1.86 | Tuberculosis |
15065882 |
Kinetic and chemical mechanism of Mycobacterium tuberculosis 1-deoxy-D-xylulose-5-phosphate isomeroreductase. |
ongoing research therapeutic application unassigned |
4 1 0 |
1.1.1.86 | Tuberculosis |
17874041 |
Toward Mycobacterium tuberculosis DXR inhibitor design: homology modeling and molecular dynamics simulations. |
causal interaction therapeutic application unassigned |
2 4 0 |